| Symbol | ARGX |
|---|---|
| Name | ARGENX SE |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | WILLEMSTRAAT 5, BREDA, 4811 AH, Netherlands |
| Telephone | +31 763030488 |
| Fax | — |
| — | |
| Website | https://www.argenx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001697862 |
| Description | argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland. Additional info from NASDAQ: |
2026-07-23 05:01
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
Read more
2026-07-23 05:00
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
Read more
2026-07-16 05:00
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
Read more
2026-07-16 05:00
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
Read more
2026-06-03 05:00
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Read more
2026-06-03 05:00
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04777734 | Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammator… | — | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Available | — | — | ClinicalTrials.gov |
| NCT04777734 | Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammator… | — | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Available | — | — | ClinicalTrials.gov |
| NCT07638566 | A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Ado… | Phase2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Not_Yet_Recruiting | 2026-09-01 | 2031-08-01 | ClinicalTrials.gov |
| NCT07638566 | A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Ado… | Phase2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Not_Yet_Recruiting | 2026-09-01 | 2031-08-01 | ClinicalTrials.gov |
| NCT07583641 | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoim… | Phase2 | Autoimmune Encephalitis (AE) | Not_Yet_Recruiting | 2026-07-13 | 2029-05-12 | ClinicalTrials.gov |
| NCT07583641 | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoim… | Phase2 | Autoimmune Encephalitis (AE) | Not_Yet_Recruiting | 2026-07-13 | 2029-05-12 | ClinicalTrials.gov |
| NCT07673627 | ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Effic… | Phase2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Recruiting | 2026-07-10 | 2028-04-01 | ClinicalTrials.gov |
| NCT07673627 | ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Effic… | Phase2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Recruiting | 2026-07-10 | 2028-04-01 | ClinicalTrials.gov |
| NCT07011589 | Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VY… | Phase1 | Epidermolysis Bullosa (EB) | Not_Yet_Recruiting | 2026-07-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT07011589 | Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VY… | Phase1 | Epidermolysis Bullosa (EB) | Not_Yet_Recruiting | 2026-07-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT07610564 | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound… | Phase1 | Multifocal Motor Neuropathy (MMN) | Not_Yet_Recruiting | 2026-06-30 | 2030-04-01 | ClinicalTrials.gov |
| NCT07610564 | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound… | Phase1 | Multifocal Motor Neuropathy (MMN) | Not_Yet_Recruiting | 2026-06-30 | 2030-04-01 | ClinicalTrials.gov |
| NCT07673601 | A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Thr… | Phase1 | Healthy Volunteers (HV) | Recruiting | 2026-06-12 | 2026-12-01 | ClinicalTrials.gov |
| NCT07673601 | A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Thr… | Phase1 | Healthy Volunteers (HV) | Recruiting | 2026-06-12 | 2026-12-01 | ClinicalTrials.gov |
| NCT07596849 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Part… | Phase3 | Graves Disease | Recruiting | 2026-06-10 | 2030-05-01 | ClinicalTrials.gov |
| NCT07570316 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Part… | Phase3 | Graves' Disease | Recruiting | 2026-06-10 | 2030-05-01 | ClinicalTrials.gov |
| NCT07596849 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Part… | Phase3 | Graves Disease | Recruiting | 2026-06-10 | 2030-05-01 | ClinicalTrials.gov |
| NCT07570316 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Part… | Phase3 | Graves' Disease | Recruiting | 2026-06-10 | 2030-05-01 | ClinicalTrials.gov |
| NCT07612020 | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered… | Phase1 | Healthy Volunteers | Recruiting | 2026-03-16 | 2027-10-01 | ClinicalTrials.gov |
| NCT07612020 | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered… | Phase1 | Healthy Volunteers | Recruiting | 2026-03-16 | 2027-10-01 | ClinicalTrials.gov |
| NCT07595653 | A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of… | — | Generalized Myasthenia Gravis (gMG) | Recruiting | 2026-02-25 | 2028-07-01 | ClinicalTrials.gov |
| NCT07595653 | A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of… | — | Generalized Myasthenia Gravis (gMG) | Recruiting | 2026-02-25 | 2028-07-01 | ClinicalTrials.gov |
| NCT07377396 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers | Phase1 | Healthy Volunteers | Recruiting | 2026-01-26 | 2026-12-31 | ClinicalTrials.gov |
| NCT07377396 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers | Phase1 | Healthy Volunteers | Recruiting | 2026-01-26 | 2026-12-31 | ClinicalTrials.gov |
| NCT07287982 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Imm… | Phase2 | Spinal Muscular Atrophy (SMA) | Recruiting | 2025-12-19 | 2029-05-28 | ClinicalTrials.gov |
| NCT07287982 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Imm… | Phase2 | Spinal Muscular Atrophy (SMA) | Recruiting | 2025-12-19 | 2029-05-28 | ClinicalTrials.gov |
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy… | Phase2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Recruiting | 2025-12-19 | 2028-03-07 | ClinicalTrials.gov |
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and … | — | Myasthenia Gravis | Recruiting | 2025-12-19 | 2028-03-07 | ClinicalTrials.gov |
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy… | Phase2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Recruiting | 2025-12-19 | 2028-03-07 | ClinicalTrials.gov |
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and … | — | Myasthenia Gravis | Recruiting | 2025-12-19 | 2028-03-07 | ClinicalTrials.gov |
| NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years … | Phase2 | Immune Thrombocytopenia (ITP) | Recruiting | 2025-10-20 | 2030-10-01 | ClinicalTrials.gov |
| NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years … | Phase2 | Immune Thrombocytopenia (ITP) | Recruiting | 2025-10-20 | 2030-10-01 | ClinicalTrials.gov |
| NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | Phase3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | 2025-09-16 | 2031-01-23 | ClinicalTrials.gov |
| NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | Phase3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | 2025-09-16 | 2031-01-23 | ClinicalTrials.gov |
| NCT06920004 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults Wi… | Phase3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | 2025-08-22 | 2030-09-01 | ClinicalTrials.gov |
| NCT06920004 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults Wi… | Phase3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | 2025-08-22 | 2030-09-01 | ClinicalTrials.gov |
| NCT06453694 | Efgartigimod for the Treatment of Acute Optic Neuritis | Phase2 | Optic Neuritis | Recruiting | 2025-08-12 | 2027-07-01 | ClinicalTrials.gov |
| NCT06453694 | Efgartigimod for the Treatment of Acute Optic Neuritis | Phase2 | Optic Neuritis | Recruiting | 2025-08-12 | 2027-07-01 | ClinicalTrials.gov |
| NCT07264426 | Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Recruiting | 2025-08-11 | 2029-10-01 | ClinicalTrials.gov |
| NCT07264426 | Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Recruiting | 2025-08-11 | 2029-10-01 | ClinicalTrials.gov |
| NCT06909214 | A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults Wit… | Phase4 | New Onset Generalized Myasthenia Gravis (gMG) | Recruiting | 2025-04-17 | 2027-05-01 | ClinicalTrials.gov |
| NCT06909214 | A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults Wit… | Phase4 | New Onset Generalized Myasthenia Gravis (gMG) | Recruiting | 2025-04-17 | 2027-05-01 | ClinicalTrials.gov |
| NCT06968338 | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2025-04-11 | 2026-03-20 | ClinicalTrials.gov |
| NCT06968338 | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2025-04-11 | 2026-03-20 | ClinicalTrials.gov |
| NCT06860633 | Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod | Phase4 | Myasthenia Gravis Crisis | Recruiting | 2025-03-06 | 2026-12-31 | ClinicalTrials.gov |
| NCT06860633 | Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod | Phase4 | Myasthenia Gravis Crisis | Recruiting | 2025-03-06 | 2026-12-31 | ClinicalTrials.gov |
| NCT06765161 | Efgartigimod in IVIG Dependent Myasthenia Gravis Patients | Phase3 | Myasthaenia Gravis | Recruiting | 2025-02-06 | 2027-01-06 | ClinicalTrials.gov |
| NCT06765161 | Efgartigimod in IVIG Dependent Myasthenia Gravis Patients | Phase3 | Myasthaenia Gravis | Recruiting | 2025-02-06 | 2027-01-06 | ClinicalTrials.gov |
| NCT06684847 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjö… | Phase3 | Primary Sjogrens Disease | Active_Not_Recruiting | 2025-01-15 | 2028-07-01 | ClinicalTrials.gov |
| NCT06684847 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjö… | Phase3 | Primary Sjogrens Disease | Active_Not_Recruiting | 2025-01-15 | 2028-07-01 | ClinicalTrials.gov |
| NCT06799416 | A Study to Assess the Safety of ARGX-109 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2025-01-14 | 2025-08-08 | ClinicalTrials.gov |
| NCT06799416 | A Study to Assess the Safety of ARGX-109 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2025-01-14 | 2025-08-08 | ClinicalTrials.gov |
| NCT06742190 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adult… | Phase3 | Multifocal Motor Neuropathy (MMN) | Active_Not_Recruiting | 2024-12-18 | 2029-12-01 | ClinicalTrials.gov |
| NCT06742190 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adult… | Phase3 | Multifocal Motor Neuropathy (MMN) | Active_Not_Recruiting | 2024-12-18 | 2029-12-01 | ClinicalTrials.gov |
| NCT06637072 | A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20… | Phase4 | Chronic Inflammatory Demyelinating Polyneuropathy | Completed | 2024-12-10 | 2026-02-19 | ClinicalTrials.gov |
| NCT06637072 | A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20… | Phase4 | Chronic Inflammatory Demyelinating Polyneuropathy | Completed | 2024-12-10 | 2026-02-19 | ClinicalTrials.gov |
| NCT06688253 | Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis | Phase4 | Myasthenia Gravis Crisis | Not_Yet_Recruiting | 2024-11-15 | 2025-03-30 | ClinicalTrials.gov |
| NCT06688253 | Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis | Phase4 | Myasthenia Gravis Crisis | Not_Yet_Recruiting | 2024-11-15 | 2025-03-30 | ClinicalTrials.gov |
| NCT06655155 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults Wit… | Phase2 | Systemic Sclerosis (SSc) | Recruiting | 2024-11-11 | 2027-09-01 | ClinicalTrials.gov |
| NCT06655155 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults Wit… | Phase2 | Systemic Sclerosis (SSc) | Recruiting | 2024-11-11 | 2027-09-01 | ClinicalTrials.gov |
| NCT06298565 | A Non-interventional, Post-authorisation Safety Study of Patients Treated With … | — | Myasthenia Gravis | Recruiting | 2024-11-04 | 2034-06-01 | ClinicalTrials.gov |
| NCT06298565 | A Non-interventional, Post-authorisation Safety Study of Patients Treated With … | — | Myasthenia Gravis | Recruiting | 2024-11-04 | 2034-06-01 | ClinicalTrials.gov |
| NCT06441682 | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Late… | Phase2 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2024-10-23 | 2026-08-01 | ClinicalTrials.gov |
| NCT06441682 | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Late… | Phase2 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2024-10-23 | 2026-08-01 | ClinicalTrials.gov |
| NCT06544499 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participa… | Phase3 | Primary Immune Thrombocytopenia (ITP) | Recruiting | 2024-10-18 | 2028-06-01 | ClinicalTrials.gov |
| NCT06544499 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participa… | Phase3 | Primary Immune Thrombocytopenia (ITP) | Recruiting | 2024-10-18 | 2028-06-01 | ClinicalTrials.gov |
| NCT06436742 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Pa… | Phase1 | Congenital Myasthenic Syndrome | Active_Not_Recruiting | 2024-09-24 | 2028-01-24 | ClinicalTrials.gov |
| NCT06436742 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Pa… | Phase1 | Congenital Myasthenic Syndrome | Active_Not_Recruiting | 2024-09-24 | 2028-01-24 | ClinicalTrials.gov |
| NCT06558279 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Oc… | Phase3 | Myasthenia Gravis, Ocular | Active_Not_Recruiting | 2024-09-18 | 2027-12-01 | ClinicalTrials.gov |
| NCT06558279 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Oc… | Phase3 | Myasthenia Gravis, Ocular | Active_Not_Recruiting | 2024-09-18 | 2027-12-01 | ClinicalTrials.gov |
| NCT05701189 | Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome | Phase2 | Guillain-Barre Syndrome | Withdrawn | 2024-09-10 | 2026-02-20 | ClinicalTrials.gov |
| NCT05701189 | Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome | Phase2 | Guillain-Barre Syndrome | Withdrawn | 2024-09-10 | 2026-02-20 | ClinicalTrials.gov |
| NCT06503731 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given b… | Phase2 | Antibody-mediated Rejection | Active_Not_Recruiting | 2024-08-30 | 2027-11-01 | ClinicalTrials.gov |
| NCT06503731 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given b… | Phase2 | Antibody-mediated Rejection | Active_Not_Recruiting | 2024-08-30 | 2027-11-01 | ClinicalTrials.gov |
| NCT06284954 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermato… | Phase2 | Dermatomyositis | Active_Not_Recruiting | 2024-08-20 | 2026-11-01 | ClinicalTrials.gov |
| NCT06284954 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermato… | Phase2 | Dermatomyositis | Active_Not_Recruiting | 2024-08-20 | 2026-11-01 | ClinicalTrials.gov |
| NCT06392386 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of… | Phase2 | Generalized Myasthenia Gravis | Recruiting | 2024-06-28 | 2026-09-30 | ClinicalTrials.gov |
| NCT06392386 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of… | Phase2 | Generalized Myasthenia Gravis | Recruiting | 2024-06-28 | 2026-09-30 | ClinicalTrials.gov |
| NCT06298552 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patie… | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2024-04-16 | 2027-06-01 | ClinicalTrials.gov |
| NCT06298552 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patie… | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2024-04-16 | 2027-06-01 | ClinicalTrials.gov |
| NCT06307626 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyro… | Phase3 | Thyroid Eye Disease | Terminated | 2024-03-28 | 2026-02-12 | ClinicalTrials.gov |
| NCT06307626 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyro… | Phase3 | Thyroid Eye Disease | Terminated | 2024-03-28 | 2026-02-12 | ClinicalTrials.gov |
| NCT06307613 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyro… | Phase3 | Thyroid Eye Disease | Terminated | 2024-03-27 | 2026-02-12 | ClinicalTrials.gov |
| NCT06307613 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyro… | Phase3 | Thyroid Eye Disease | Terminated | 2024-03-27 | 2026-02-12 | ClinicalTrials.gov |
| NCT05907096 | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Gra… | Phase2 | Delayed Graft Function | Active_Not_Recruiting | 2024-02-17 | 2026-07-31 | ClinicalTrials.gov |
| NCT05907096 | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Gra… | Phase2 | Delayed Graft Function | Active_Not_Recruiting | 2024-02-17 | 2026-07-31 | ClinicalTrials.gov |
| NCT06078553 | A Natural History Study in Participants With Congenital Myasthenic Syndromes (C… | — | Congenital Myasthenic Syndrome | Recruiting | 2024-02-13 | 2027-06-01 | ClinicalTrials.gov |
| NCT06078553 | A Natural History Study in Participants With Congenital Myasthenic Syndromes (C… | — | Congenital Myasthenic Syndrome | Recruiting | 2024-02-13 | 2027-06-01 | ClinicalTrials.gov |
| NCT06299748 | A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcom… | — | Myasthenia Gravis | Recruiting | 2023-11-30 | 2033-12-01 | ClinicalTrials.gov |
| NCT06299748 | A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcom… | — | Myasthenia Gravis | Recruiting | 2023-11-30 | 2033-12-01 | ClinicalTrials.gov |
| NCT05988073 | A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy | — | Multifocal Motor Neuropathy | Active_Not_Recruiting | 2023-11-29 | 2028-12-31 | ClinicalTrials.gov |
| NCT06203457 | Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Pati… | Phase2 | Primary Sjögren's Syndrome | Completed | 2023-11-29 | 2025-02-03 | ClinicalTrials.gov |
| NCT06203457 | Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Pati… | Phase2 | Primary Sjögren's Syndrome | Completed | 2023-11-29 | 2025-02-03 | ClinicalTrials.gov |
| NCT05988073 | A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy | — | Multifocal Motor Neuropathy | Active_Not_Recruiting | 2023-11-29 | 2028-12-31 | ClinicalTrials.gov |
| NCT05979441 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulati… | Phase3 | Myositis | Enrolling_By_Invitation | 2023-09-12 | 2028-09-01 | ClinicalTrials.gov |
| NCT05979441 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulati… | Phase3 | Myositis | Enrolling_By_Invitation | 2023-09-12 | 2028-09-01 | ClinicalTrials.gov |
| NCT05927415 | A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgar… | Phase1 | Renal Impairment | Completed | 2023-07-17 | 2024-06-12 | ClinicalTrials.gov |
| NCT05927415 | A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgar… | Phase1 | Renal Impairment | Completed | 2023-07-17 | 2024-06-12 | ClinicalTrials.gov |
| NCT05918978 | Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | Phase2 | Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | Terminated | 2023-06-20 | 2024-08-15 | ClinicalTrials.gov |
| NCT05918978 | Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | Phase2 | Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | Terminated | 2023-06-20 | 2024-08-15 | ClinicalTrials.gov |
| NCT05817669 | A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primar… | Phase2 | Primary Sjögren's Syndrome | Completed | 2023-04-04 | 2024-02-12 | ClinicalTrials.gov |
| NCT05817669 | A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primar… | Phase2 | Primary Sjögren's Syndrome | Completed | 2023-04-04 | 2024-02-12 | ClinicalTrials.gov |
| NCT05681481 | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of … | Phase3 | Bullous Pemphigoid | Terminated | 2023-03-22 | 2025-03-20 | ClinicalTrials.gov |
| NCT05681481 | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of … | Phase3 | Bullous Pemphigoid | Terminated | 2023-03-22 | 2025-03-20 | ClinicalTrials.gov |
| NCT05817435 | A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefi… | Phase1 | Bioequivalence | Completed | 2023-03-13 | 2023-05-12 | ClinicalTrials.gov |
| NCT05817435 | A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefi… | Phase1 | Bioequivalence | Completed | 2023-03-13 | 2023-05-12 | ClinicalTrials.gov |
| NCT05670704 | A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and… | Phase1 | Healthy Volunteers | Completed | 2023-02-21 | 2024-08-08 | ClinicalTrials.gov |
| NCT05670704 | A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and… | Phase1 | Healthy Volunteers | Completed | 2023-02-21 | 2024-08-08 | ClinicalTrials.gov |
| NCT05810961 | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients … | Phase2 | Membranous Nephropathy | Terminated | 2023-02-20 | 2024-08-05 | ClinicalTrials.gov |
| NCT05810961 | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients … | Phase2 | Membranous Nephropathy | Terminated | 2023-02-20 | 2024-08-05 | ClinicalTrials.gov |
| NCT05405361 | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy… | Phase2 | Multifocal Motor Neuropathy (MMN) | Active_Not_Recruiting | 2023-01-18 | 2029-09-30 | ClinicalTrials.gov |
| NCT05405361 | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy… | Phase2 | Multifocal Motor Neuropathy (MMN) | Active_Not_Recruiting | 2023-01-18 | 2029-09-30 | ClinicalTrials.gov |
| NCT05523167 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult… | Phase2 | Active Idiopathic Inflammatory Myopathy | Completed | 2022-10-12 | 2026-07-02 | ClinicalTrials.gov |
| NCT05523167 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult… | Phase2 | Active Idiopathic Inflammatory Myopathy | Completed | 2022-10-12 | 2026-07-02 | ClinicalTrials.gov |
| NCT05633407 | Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | Phase2 | Postural Orthostatic Tachycardia Syndrome | Completed | 2022-09-23 | 2024-04-18 | ClinicalTrials.gov |
| NCT05633407 | Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | Phase2 | Postural Orthostatic Tachycardia Syndrome | Completed | 2022-09-23 | 2024-04-18 | ClinicalTrials.gov |
| NCT05374590 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efga… | Phase2 | Generalized Myasthenia Gravis | Enrolling_By_Invitation | 2022-08-18 | 2029-09-01 | ClinicalTrials.gov |
| NCT05374590 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efga… | Phase2 | Generalized Myasthenia Gravis | Enrolling_By_Invitation | 2022-08-18 | 2029-09-01 | ClinicalTrials.gov |
| NCT05267600 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pe… | Phase2 | Bullous Pemphigoid | Completed | 2022-06-09 | 2024-09-13 | ClinicalTrials.gov |
| NCT05267600 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pe… | Phase2 | Bullous Pemphigoid | Completed | 2022-06-09 | 2024-09-13 | ClinicalTrials.gov |
| NCT05225675 | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmaco… | Phase2 | Multifocal Motor Neuropathy | Completed | 2022-03-31 | 2024-06-04 | ClinicalTrials.gov |
| NCT05225675 | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmaco… | Phase2 | Multifocal Motor Neuropathy | Completed | 2022-03-31 | 2024-06-04 | ClinicalTrials.gov |
| NCT04980495 | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Re… | Phase3 | Generalized Myasthenia Gravis | Completed | 2021-12-16 | 2025-10-06 | ClinicalTrials.gov |
| NCT04980495 | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Re… | Phase3 | Generalized Myasthenia Gravis | Completed | 2021-12-16 | 2025-10-06 | ClinicalTrials.gov |
| NCT04812925 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcut… | Phase3 | Primary Immune Thrombocytopenia | Active_Not_Recruiting | 2021-11-17 | 2026-10-01 | ClinicalTrials.gov |
| NCT05163834 | Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV | Phase1 | Healthy Volunteers | Completed | 2021-11-17 | 2022-03-08 | ClinicalTrials.gov |
| NCT05163834 | Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV | Phase1 | Healthy Volunteers | Completed | 2021-11-17 | 2022-03-08 | ClinicalTrials.gov |
| NCT04812925 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcut… | Phase3 | Primary Immune Thrombocytopenia | Active_Not_Recruiting | 2021-11-17 | 2026-10-01 | ClinicalTrials.gov |
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod A… | Phase2 | Generalized Myasthenia Gravis | Recruiting | 2021-10-26 | 2027-03-01 | ClinicalTrials.gov |
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod A… | Phase2 | Generalized Myasthenia Gravis | Recruiting | 2021-10-26 | 2027-03-01 | ClinicalTrials.gov |
| NCT04598477 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulati… | Phase3 | Pemphigus Vulgaris | Terminated | 2021-07-15 | 2024-03-25 | ClinicalTrials.gov |
| NCT04598477 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulati… | Phase3 | Pemphigus Vulgaris | Terminated | 2021-07-15 | 2024-03-25 | ClinicalTrials.gov |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidin… | Phase2 | Myelodysplastic Syndromes | Withdrawn | 2021-05-06 | 2025-01-28 | ClinicalTrials.gov |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidin… | Phase2 | Myelodysplastic Syndromes | Withdrawn | 2021-05-06 | 2025-01-28 | ClinicalTrials.gov |
| NCT04818671 | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Admini… | Phase3 | Generalized Myasthenia Gravis | Completed | 2021-04-26 | 2024-12-31 | ClinicalTrials.gov |
| NCT04818671 | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Admini… | Phase3 | Generalized Myasthenia Gravis | Completed | 2021-04-26 | 2024-12-31 | ClinicalTrials.gov |
| NCT04735432 | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administe… | Phase3 | Generalized Myasthenia Gravis | Completed | 2021-02-05 | 2021-12-13 | ClinicalTrials.gov |
| NCT04735432 | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administe… | Phase3 | Generalized Myasthenia Gravis | Completed | 2021-02-05 | 2021-12-13 | ClinicalTrials.gov |
| NCT04687072 | A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous i… | Phase3 | Primary Immune Thrombocytopenia | Completed | 2020-12-16 | 2023-10-09 | ClinicalTrials.gov |
| NCT04687072 | A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous i… | Phase3 | Primary Immune Thrombocytopenia | Completed | 2020-12-16 | 2023-10-09 | ClinicalTrials.gov |
| NCT04598451 | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efga… | Phase3 | Pemphigus Vulgaris | Completed | 2020-12-01 | 2023-08-22 | ClinicalTrials.gov |
| NCT04598451 | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efga… | Phase3 | Pemphigus Vulgaris | Completed | 2020-12-01 | 2023-08-22 | ClinicalTrials.gov |
| NCT04280718 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulati… | Phase2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Active_Not_Recruiting | 2020-09-18 | 2027-04-30 | ClinicalTrials.gov |
| NCT04280718 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulati… | Phase2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Active_Not_Recruiting | 2020-09-18 | 2027-04-30 | ClinicalTrials.gov |
| NCT04564066 | A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intraven… | Phase1 | Healthy Volunteers | Completed | 2020-08-18 | 2021-02-11 | ClinicalTrials.gov |
| NCT04564066 | A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intraven… | Phase1 | Healthy Volunteers | Completed | 2020-08-18 | 2021-02-11 | ClinicalTrials.gov |
| NCT04532125 | SAD and MAD Study With IV and SC Doses of ARGX-117 | Phase1 | Healthy Volunteers | Completed | 2020-08-03 | 2022-08-26 | ClinicalTrials.gov |
| NCT04532125 | SAD and MAD Study With IV and SC Doses of ARGX-117 | Phase1 | Healthy Volunteers | Completed | 2020-08-03 | 2022-08-26 | ClinicalTrials.gov |
| NCT04274452 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients Wit… | Phase3 | Primary Immune Thrombocytopenia (ITP) | Withdrawn | 2020-06-29 | 2021-09-01 | ClinicalTrials.gov |
| NCT04274452 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients Wit… | Phase3 | Primary Immune Thrombocytopenia (ITP) | Withdrawn | 2020-06-29 | 2021-09-01 | ClinicalTrials.gov |
| NCT04225156 | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Pa… | Phase3 | Primary Immune Thrombocytopenia | Completed | 2020-06-02 | 2026-03-11 | ClinicalTrials.gov |
| NCT04225156 | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Pa… | Phase3 | Primary Immune Thrombocytopenia | Completed | 2020-06-02 | 2026-03-11 | ClinicalTrials.gov |
| NCT04281472 | A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efga… | Phase2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Completed | 2020-04-15 | 2023-05-11 | ClinicalTrials.gov |
| NCT04281472 | A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efga… | Phase2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Completed | 2020-04-15 | 2023-05-11 | ClinicalTrials.gov |
| NCT04241549 | A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Dia… | Phase1 | Leukemia, Myeloid, Acute | Completed | 2020-03-25 | 2021-07-19 | ClinicalTrials.gov |
| NCT04241549 | A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Dia… | Phase1 | Leukemia, Myeloid, Acute | Completed | 2020-03-25 | 2021-07-19 | ClinicalTrials.gov |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Partici… | Phase1 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-12-23 | 2027-05-15 | ClinicalTrials.gov |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Partici… | Phase1 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-12-23 | 2027-05-15 | ClinicalTrials.gov |
| NCT04188379 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients Wit… | Phase3 | Primary Immune Thrombocytopenia | Completed | 2019-12-16 | 2022-02-03 | ClinicalTrials.gov |
| NCT04188379 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients Wit… | Phase3 | Primary Immune Thrombocytopenia | Completed | 2019-12-16 | 2022-02-03 | ClinicalTrials.gov |
| NCT04023526 | A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Ac… | Phase2 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-07-29 | 2026-05-15 | ClinicalTrials.gov |
| NCT04023526 | A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Ac… | Phase2 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-07-29 | 2026-05-15 | ClinicalTrials.gov |
| NCT04073589 | Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2019-07-17 | 2019-09-26 | ClinicalTrials.gov |
| NCT04073589 | Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2019-07-17 | 2019-09-26 | ClinicalTrials.gov |
| NCT03770403 | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis … | Phase3 | Generalized Myasthenia Gravis | Completed | 2019-03-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT03770403 | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis … | Phase3 | Generalized Myasthenia Gravis | Completed | 2019-03-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT03669588 | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who… | Phase3 | Generalized Myasthenia Gravis | Completed | 2018-08-22 | 2020-04-06 | ClinicalTrials.gov |
| NCT03669588 | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who… | Phase3 | Generalized Myasthenia Gravis | Completed | 2018-08-22 | 2020-04-06 | ClinicalTrials.gov |
| NCT03334058 | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients Wit… | Phase2 | Pemphigus Vulgaris | Completed | 2017-10-18 | 2020-10-28 | ClinicalTrials.gov |
| NCT03334058 | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients Wit… | Phase2 | Pemphigus Vulgaris | Completed | 2017-10-18 | 2020-10-28 | ClinicalTrials.gov |
| NCT03334084 | A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Fo… | Phase1 | Bioavailability Study | Completed | 2017-10-11 | 2018-09-19 | ClinicalTrials.gov |
| NCT03334084 | A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Fo… | Phase1 | Bioavailability Study | Completed | 2017-10-11 | 2018-09-19 | ClinicalTrials.gov |
| NCT03102593 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in P… | Phase2 | Primary Immune Thrombocytopenia | Completed | 2017-03-13 | 2019-04-09 | ClinicalTrials.gov |
| NCT03102593 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in P… | Phase2 | Primary Immune Thrombocytopenia | Completed | 2017-03-13 | 2019-04-09 | ClinicalTrials.gov |
| NCT02965573 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in P… | Phase2 | Myasthenia Gravis | Completed | 2016-12-30 | 2017-10-20 | ClinicalTrials.gov |
| NCT02965573 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in P… | Phase2 | Myasthenia Gravis | Completed | 2016-12-30 | 2017-10-20 | ClinicalTrials.gov |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly … | Phase1 | Leukemia, Myeloid, Acute | Completed | 2016-12-01 | 2022-08-01 | ClinicalTrials.gov |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly … | Phase1 | Leukemia, Myeloid, Acute | Completed | 2016-12-01 | 2022-08-01 | ClinicalTrials.gov |
| NCT03457649 | IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of … | Phase1 | Healthy Volunteers | Completed | 2015-09-09 | 2017-02-21 | ClinicalTrials.gov |
| NCT03457649 | IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of … | Phase1 | Healthy Volunteers | Completed | 2015-09-09 | 2017-02-21 | ClinicalTrials.gov |
| NCT02759250 | A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) | Phase1 | Cancer | Completed | 2015-02-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02759250 | A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) | Phase1 | Cancer | Completed | 2015-02-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02055066 | A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | Phase1 | Cancer | Completed | 2014-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02055066 | A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | Phase1 | Cancer | Completed | 2014-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01813539 | A Study of ARGX-110 in Participants With Advanced Malignancies | Phase1 | Neoplasms | Completed | 2013-02-27 | 2020-07-10 | ClinicalTrials.gov |
| NCT01813539 | A Study of ARGX-110 in Participants With Advanced Malignancies | Phase1 | Neoplasms | Completed | 2013-02-27 | 2020-07-10 | ClinicalTrials.gov |
Total clinical trials: 186
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Efgartigimod PH20 SC PFS | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07673627 |
| Placebo IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07673627 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07673627 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | ACTIVE_NOT_RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | ACTIVE_NOT_RECRUITING | NCT06436742 |
| PBO | Other | Phase PHASE2 | Active Idiopathic Inflammatory Myopathy | COMPLETED | NCT05523167 |
| EFG PH20 SC | Other | Phase PHASE2 | Active Idiopathic Inflammatory Myopathy | COMPLETED | NCT05523167 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Placebo PH20 SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Efgartigimod PH20 (ARGX-113) SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Placebo IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Efgartigimod IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | RECRUITING | NCT07570316 |
| Placebo PH20 SC | Other | Phase PHASE3 | Myasthenia Gravis, Ocular | ACTIVE_NOT_RECRUITING | NCT06558279 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myasthenia Gravis, Ocular | ACTIVE_NOT_RECRUITING | NCT06558279 |
| Placebo PH20 SC - prefilled syringe | Other | Phase PHASE2 | Antibody-mediated Rejection | ACTIVE_NOT_RECRUITING | NCT06503731 |
| Efgartigimod PH20 SC - prefilled syringe | Other | Phase PHASE2 | Antibody-mediated Rejection | ACTIVE_NOT_RECRUITING | NCT06503731 |
| Efgartigimod PH20 SC PFS | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07673627 |
| Placebo IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07673627 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07673627 |
| Adimanebart SC - formulation C | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07673601 |
| Adimanebart SC - formulation B | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07673601 |
| Adimanebart SC - formulation A | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07673601 |
| Adimanebart IV | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07673601 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Efgartigimod IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | NOT_YET_RECRUITING | NCT07638566 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Placebo IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Efgartigimod IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Efgartigimod IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| empasiprubart IV | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07612020 |
| empasiprubart SC AI | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07612020 |
| Empasiprubart IV | Other | Phase PHASE1 | Multifocal Motor Neuropathy (MMN) | NOT_YET_RECRUITING | NCT07610564 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT06742190 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Graves Disease | NOT_YET_RECRUITING | NCT07596849 |
| Placebo PH20 SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Efgartigimod PH20 (ARGX-113) SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Placebo PH20 SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Efgartigimod PH20 (ARGX-113) SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Placebo PH20 SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Efgartigimod PH20 (ARGX-113) SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Placebo PH20 SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Efgartigimod PH20 (ARGX-113) SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Placebo PH20 SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Efgartigimod PH20 (ARGX-113) SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Venetoclax | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Placebo PH20 SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Efgartigimod PH20 (ARGX-113) SC | Other | Phase PHASE2 | Autoimmune Encephalitis (AE) | NOT_YET_RECRUITING | NCT07583641 |
| Venetoclax | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Venetoclax | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Venetoclax | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Venetoclax | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Venetoclax | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Placebo | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| ARGX-117 | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Placebo | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| ARGX-117 | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Placebo | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| ARGX-117 | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Placebo | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| ARGX-117 | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Placebo PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Graves' Disease | NOT_YET_RECRUITING | NCT07570316 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod IV | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05927415 |
| efgartigimod administration | Other | Phase PHASE3 | Myasthaenia Gravis | RECRUITING | NCT06765161 |
| ARGX-111 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02055066 |
| ARGX-110 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02759250 |
| ARGX-113 with rHuPH20 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04073589 |
| ARGX-113 | Other | Phase PHASE1 | Bioavailability Study | COMPLETED | NCT03334084 |
| Placebo | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | WITHDRAWN | NCT04274452 |
| efgartigimod | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | WITHDRAWN | NCT04274452 |
| ARGX-113 | Other | Phase PHASE2 | Pemphigus Vulgaris | COMPLETED | NCT03334058 |
| efgartigimod PH20 SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564066 |
| efgartigimod IV | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564066 |
| Placebo | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT03669588 |
| ARGX-113 | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT03669588 |
| PNEUMOVAX 23 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05163834 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05163834 |
| Efgartigimod | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05163834 |
| Cusatuzumab | Other | Phase PHASE2 | Myelodysplastic Syndromes | WITHDRAWN | NCT04264806 |
| Azacitidine | Other | Phase PHASE2 | Myelodysplastic Syndromes | WITHDRAWN | NCT04264806 |
| Placebo PH20 SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04532125 |
| ARGX-117 PH20 SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04532125 |
| placebo + rHuPH20 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04532125 |
| ARGX-117 + rHuPH20 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04532125 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04532125 |
| ARGX-117 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04532125 |
| efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04735432 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04735432 |
| ARGX-113 | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT03770403 |
| Placebo | Other | Phase PHASE2 | Primary Immune Thrombocytopenia | COMPLETED | NCT03102593 |
| ARGX-113 | Other | Phase PHASE2 | Primary Immune Thrombocytopenia | COMPLETED | NCT03102593 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT04241549 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT04241549 |
| AZA | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT03030612 |
| ARGX-110 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT03030612 |
| ARGX-110 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01813539 |
| efgartigimod PH20 SC as a vial + syringe presentation | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT05817435 |
| efgartigimod PH20 SC as a prefilled syringe presentation | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT05817435 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03457649 |
| ARGX-113 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03457649 |
| placebo in stage B | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | COMPLETED | NCT04281472 |
| efgartigimod PH20 SC in stage B | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | COMPLETED | NCT04281472 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05670704 |
| ARGX-119 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05670704 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis | COMPLETED | NCT02965573 |
| ARGX-113 | Other | Phase PHASE2 | Myasthenia Gravis | COMPLETED | NCT02965573 |
| prednisone | Other | Phase PHASE3 | Pemphigus Vulgaris | COMPLETED | NCT04598451 |
| Placebo | Other | Phase PHASE3 | Pemphigus Vulgaris | COMPLETED | NCT04598451 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Pemphigus Vulgaris | COMPLETED | NCT04598451 |
| Placebo | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| ARGX-117 | Other | Phase PHASE2 | Multifocal Motor Neuropathy | COMPLETED | NCT05225675 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Immune Thrombocytopenia | COMPLETED | NCT04687072 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Immune Thrombocytopenia | COMPLETED | NCT04687072 |
| IV efgartigimod | Other | Phase PHASE4 | Myasthenia Gravis Crisis | NOT_YET_RECRUITING | NCT06688253 |
| placebo | Other | Phase PHASE2 | Membranous Nephropathy | TERMINATED | NCT05810961 |
| efgartigimod IV | Other | Phase PHASE2 | Membranous Nephropathy | TERMINATED | NCT05810961 |
| Placebo | Other | Phase PHASE3 | Primary Immune Thrombocytopenia | COMPLETED | NCT04188379 |
| efgartigimod | Other | Phase PHASE3 | Primary Immune Thrombocytopenia | COMPLETED | NCT04188379 |
| prednisone | Other | Phase PHASE3 | Pemphigus Vulgaris | TERMINATED | NCT04598477 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Pemphigus Vulgaris | TERMINATED | NCT04598477 |
| Venetoclax | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Azacitidine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Cusatuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04150887 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome | COMPLETED | NCT05633407 |
| Efgartigimod | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome | COMPLETED | NCT05633407 |
| Efgartigimod | Other | Phase PHASE1 | Epidermolysis Bullosa (EB) | NOT_YET_RECRUITING | NCT07011589 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | ACTIVE_NOT_RECRUITING | NCT04280718 |
| Efgartigimod | Other | Phase PHASE4 | Myasthenia Gravis Crisis | RECRUITING | NCT06860633 |
| Placebo | Other | Phase PHASE2 | Primary Sjögren's Syndrome | COMPLETED | NCT05817669 |
| Efgartigimod | Other | Phase PHASE2 | Primary Sjögren's Syndrome | COMPLETED | NCT05817669 |
| PBO | Other | Phase PHASE2 | Active Idiopathic Inflammatory Myopathy | ACTIVE_NOT_RECRUITING | NCT05523167 |
| EFG PH20 SC | Other | Phase PHASE2 | Active Idiopathic Inflammatory Myopathy | ACTIVE_NOT_RECRUITING | NCT05523167 |
| Cusatuzumab | Other | Phase PHASE2 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04023526 |
| Azacitidine | Other | Phase PHASE2 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04023526 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06799416 |
| ARGX-109 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06799416 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Immune Thrombocytopenia | ACTIVE_NOT_RECRUITING | NCT04812925 |
| Efgartigimod PH20 SC | Other | Phase PHASE4 | New Onset Generalized Myasthenia Gravis (gMG) | RECRUITING | NCT06909214 |
| Placebo | Other | Phase PHASE2 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT05405361 |
| ARGX-117 | Other | Phase PHASE2 | Multifocal Motor Neuropathy (MMN) | ACTIVE_NOT_RECRUITING | NCT05405361 |
| Placebo IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Efgartigimod IV | Other | Phase PHASE2 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07194850 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo IV | Other | Phase PHASE2 | Dermatomyositis | ACTIVE_NOT_RECRUITING | NCT06284954 |
| Empasiprubart IV | Other | Phase PHASE2 | Dermatomyositis | ACTIVE_NOT_RECRUITING | NCT06284954 |
| Efgartigimod | Other | Phase PHASE2 | Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | TERMINATED | NCT05918978 |
| Prednisone | Other | Phase PHASE2 | Bullous Pemphigoid | COMPLETED | NCT05267600 |
| placebo | Other | Phase PHASE2 | Bullous Pemphigoid | COMPLETED | NCT05267600 |
| efgartigimod PH20 SC | Other | Phase PHASE2 | Bullous Pemphigoid | COMPLETED | NCT05267600 |
| Placebo IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT06298552 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT06298552 |
| Efgartigimod IV | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04980495 |
| Placebo | Other | Phase PHASE2 | Optic Neuritis | RECRUITING | NCT06453694 |
| Efgartigimod Alfa | Other | Phase PHASE2 | Optic Neuritis | RECRUITING | NCT06453694 |
| Placebo PH20 SC | Other | Phase PHASE3 | Myasthenia Gravis, Ocular | ACTIVE_NOT_RECRUITING | NCT06558279 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myasthenia Gravis, Ocular | ACTIVE_NOT_RECRUITING | NCT06558279 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT04818671 |
| Efgartigimod | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT06299748 |
| efgartigimod | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT06298565 |
| Efgartigimod IV | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT04833894 |
| Efgartigimod | Other | Phase PHASE2 | Primary Sjögren's Syndrome | COMPLETED | NCT06203457 |
| Prednisone | Other | Phase PHASE3 | Bullous Pemphigoid | TERMINATED | NCT05681481 |
| efgartigimod PH20 SC | Other | Phase PHASE3 | Bullous Pemphigoid | TERMINATED | NCT05681481 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07377396 |
| ARGX-124 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07377396 |
| Placebo IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Empasiprubart IV | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT07091630 |
| Intravenous Immunoglobulin (IVIg) | Other | Phase PHASE2 | Guillain-Barre Syndrome | WITHDRAWN | NCT05701189 |
| Efgartigimod Alfa-Fcab | Other | Phase PHASE2 | Guillain-Barre Syndrome | WITHDRAWN | NCT05701189 |
| IVIg-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | RECRUITING | NCT06742190 |
| Empasiprubart-placebo | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | RECRUITING | NCT06742190 |
| IVIG (Intravenous Immunoglobulin) | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | RECRUITING | NCT06742190 |
| Empasiprubart | Other | Phase PHASE3 | Multifocal Motor Neuropathy (MMN) | RECRUITING | NCT06742190 |
| Placebo PH20 SC | Other | Phase PHASE3 | Thyroid Eye Disease | TERMINATED | NCT06307626 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Thyroid Eye Disease | TERMINATED | NCT06307626 |
| Placebo PH20 SC | Other | Phase PHASE3 | Thyroid Eye Disease | TERMINATED | NCT06307613 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Thyroid Eye Disease | TERMINATED | NCT06307613 |
| efgartigimod | Other | Phase PHASE3 | Primary Immune Thrombocytopenia | COMPLETED | NCT04225156 |
| Placebo PH20 SC - prefilled syringe | Other | Phase PHASE2 | Antibody-mediated Rejection | RECRUITING | NCT06503731 |
| Efgartigimod PH20 SC - prefilled syringe | Other | Phase PHASE2 | Antibody-mediated Rejection | RECRUITING | NCT06503731 |
| Placebo | Other | Phase PHASE2 | Delayed Graft Function | ACTIVE_NOT_RECRUITING | NCT05907096 |
| ARGX-117 | Other | Phase PHASE2 | Delayed Graft Function | ACTIVE_NOT_RECRUITING | NCT05907096 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | AVAILABLE | NCT04777734 |
| Efgartigimod PH20 SC | Other | Phase PHASE4 | Chronic Inflammatory Demyelinating Polyneuropathy | COMPLETED | NCT06637072 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06441682 |
| ARGX-119 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06441682 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| IVIg-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart-placebo | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| IVIg | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| empasiprubart | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyneuropathy | RECRUITING | NCT06920004 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Placebo IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod IV | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT06544499 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06392386 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| ARGX-119 | BIOLOGICAL | Phase PHASE2 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06441682 |
| Placebo | OTHER | Phase PHASE2 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06441682 |
Total products: 643